Drugs / cetuximab-800CW
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05499065 | Mar 2023 → Oct 2024 | head and neck squamous cell carcinoma | University Medical Center Groningen | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cetuximab-800CW | “Administrate 75mg cetuximab + 15mg cetuximab-800CW for fluorescence visualization” NCT05499065 ↗ |